MedTrace Logo

Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND

NCT02870634 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-03-17

No results posted yet for this study

Summary

Multicenter, open-label , single and multiple dose-escalation and pharmacokinetic study

Conditions

Interventions

DRUG

Cu(II)ATSM

copper-containing synthetic small molecule

Sponsors & Collaborators

  • Collaborative Medicinal Development Pty Limited

    lead INDUSTRY

Principal Investigators

  • Dominic Rowe, MD · Macquarie University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-16
Primary Completion
2019-10-30
Completion
2020-01-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02870634 on ClinicalTrials.gov